Secondary Schizophrenia (141 page)

Association (IHA) and the World

10
:167–76.

R. H.,
et al.
Evidence of

Federation of Neurology (WFN)

5. Lyon R. L. Huntington’s chorea in

presymptomatic cognitive decline

Research Group on Huntington’s

the Moray Firth area. Br Med J,

in Huntington’s disease. J Clin

Chorea. Guidelines for the

1962.
1
:1301–6.

Exp Neuropsychol, 1992.
14
:
molecular genetics predictive test

6. Wexler N. S., Bonilla E., Young A.

961–75.

in Huntington’s disease.

B.,
et al.
Huntington’s disease in
16. Foroud T., Siemers E., Kleindorfer

Neurology, 1994.
44
:1533–6.

Venezuela and gene linkage.

D.,
et al.
Cognitive scores of

25. Schulman J. D., Black S. H.,

Cytogenet Cell Genet, 1984.

carriers of Huntingont’s disease

Handyside A.,
et al.

37
:605. (Abstract).

gene compared to non-carriers.

Preimplantation genetic testing

7. Gusella J. F., Wexler N. S.,

Ann Neurol, 1995.
37
:657–64.

for Huntington disease and

Conneally P. M.,
et al.
A

17. Leroi I., O’Hearn E., Marsh L.,

certain other dominantly

polymorphic DNA marker

et al.
Psychopathology in patients
inherited disorders. Clin Genet,

genetically linked to Huntington’s

with degenerative cerebellar

1996.
49
:57–8.

disease. Nature, 1983.
306
:
diseases: a comparison to

26. Kremer B., Goldberg P., Andrew S.

234–8.

Huntington’s disease. Am J

E.,
et al.
A worldwide study of the
8. Huntington’s Disease

Psychiatry, 2002.
159
:1306–
Huntington’s disease mutation.

Collaborative Research Group.

14.

The sensitivity and sensitivity of

A novel gene containing a

18. Folstein S. E., Abbott M. H.,

measuring CAG repeats. N Engl J

trinucleotide repeat that is

Chase G. A.,
et al.
The association
Med, 1994.
330
:1401–6.

expanded and unstable on

of affective disorder with

27. Margolis R. L., Ross C. A.

Huntington’s disease

Huntington’s disease in a case

Diagnosis of Huntington disease.

chromosomes. Cell, 1993.

series and in families. Psychol

Clin Chem, 2003.
49
:1726–32.

72
:971–83.

Med, 1983.
13
:537–42.

28. McInnis M. G. Anticipation: an

9. Morris M. Dementia and

19. Reed T. E., Chandler J. H.

old idea in new genes. Am J Hum

cognitive changes in Huntington’s

Huntington’s chorea in Michigan:

Genet, 1996.
59
:973–9.

disease. Adv Neurol, 1995.

I. Demography and genetics. Am J

29. Duyao M., Ambrose C., Myers R.,

65
:187–200.

Hum Genet, 1958.
10
:210–25.

et al.
Trinucleotide repeat length
10. Saint-Cyr J. A., Taylor A. E., Lang

20. Young A. B., Shoulson I., Penney

instability and age of onset in

A. E. Procedural learning and

J. B.,
et al.
Huntington’s disease in
Huntington’s disease. Nat Genet,

neostriatal dysfunction in man.

Venezuela: neurologic features

1993.
4
:387–92.

Brain, 1988.
111
:941–59.

and functional decline. Neurology,

30. MacDonald M. E., Vonsattel J. P.,

11. Shoulson I. Huntington’s disease:

1986.
36
:244–9.

Shrinidhi J.,
et al.
Evidence for the
cognitive and psychiatric features.

21. Jernigan T. L., Salmon D. P.,

GluR6 gene associated with

Neuropsychiatry Neuropsychol

Butters N.,
et al.
Cerebral

younger onset age of Huntington’s

Behav Neurol, 1990.
3
:15–
structure on MRI. Part II: specific

disease. Neurology, 1999.
47
:155–
355

22.

changes in Alzheimer’s and

60.

Organic Syndromes of Schizophrenia – Section 3

31. Panas M., Avramopoulos D.,

Huntington’s Disease and

trinucleotide repeats. Nat Genet,

Karadima0 G.,
et al.

schizophrenia-like psychosis in a

1992.
2
:186–91.

Apolipoprotein E and presenilin-1

Huntington’s disease pedigree.

51. Cummings J. L. Frontal-

genotypes in Huntington’s

Clin Pract Epidemiol Ment Health,

subcortical circuits and human

disease. J Neurol, 1999.

2006.
2
:1.

behaviour. Arch Neurol, 1993.

246
:574–7.

42. Basset A. S., Honer W. G.

50
:873–80.

32. Duyao M. P., Auerbach A. B.,

Evidence for anticipation in

52. Rajkowska G., Selemon L. D.,

Ryan A.,
et al.
Inactivation of the
schizophrenia. Am J Hum Genet,

Goldman-Rakic P. S. Neuronal

mouse Huntington’s disease gene

1994.
54
:864–70.

and glial somal size in the

homolog Hdh. Science, 1995.
269
:
43. ODonovan M. C., Guy C.,

prefrontal cortex: a postmortem

407–10.

Craddock N.,
et al.
Expanded

morphometric study of

33. Everett C. M., Wood N. W.

CAG repeats in schizophrenia and

schizophrenia and Huntington’s

Trinucleotide repeats and

bipolar disorder. Nat Genet, 1995.

disease. Arch Gen Psychiatry,

neurodegenerative disease. Brain,

10
:380–1.

1998.
55
:215–24.

2004.
127
:2385–405.

44. Morris A. G., Gaitonde E.,

53. Gold J. M., Goldberg T. E.,

34. Folstein S. E., Chase G. A., Wahl

McKenna P. J.,
et al.
CAG repeat

Weinberger D. R. Prefrontal

W. E.,
et al.
Huntington disease in
expansions and schizophrenia:

function and schizophrenic

Maryland: clinical aspects of

association with disease in females

symptoms. Neuropsychiatry

racial variation. Am J Hum Genet,

and with early age-at-onset. Hum

Neuropsychol Behav Neurol, 1992.

1987.
41
:168–79.

Mol Genet, 1995.
4
:1957–61.

5
:253–61.

35. Shiwach R. Psychopathology in

45. Rubinsztein D. C., Leggo J.,

54. Tamlyn D., McKenna P. J.,

Huntington’s disease patients.

Goodburn S.,
et al.
Huntington’s

Mortimer A. M.,
et al.
Memory

Acta Psychiatr Scand, 1994.

Disease (HD) gene CAG repeats

impairment in schizophrenia: its

90
:241–6.

in schizophrenic patients shows

extent, affiliations and

36. Beckson M., Cummings J. L.

overlap of the normal and HD

neuropsychological character.

Psychosis in basal ganglia

affected ranges but absence of

Psychol Med, 1992.
22
:101–15.

disorders. Neuropsychiatry

correlation with schizophrenia. J

55. Hanes K. R., Andrewes D. G.,

Neuropsychol Behav Neurol, 1992.

Med Genet, 1994.
31
:690–3.

Pantelis C.,
et al.
Subcortical

5
:126–31.

46. Jain S., Leggo J., De Lisi L. E.,
et al.

dysfunction in schizophrenia:

37. McHugh P. R., Folstein M. F.

Analysis of thirteen trinucleotide

comparison with Parkinson’s

(1975). Psychiatric syndromes of

repeat loci as candidate genes for

disease and Huntington’s

Huntington’s chorea. In

schizophrenia and bipolar

disease. Schizophr Res, 1996.
19
:
Psychiatric Aspects of Neurological

disorder. Am J Med Genet

121–8.

Disease, Benson D. F., Bulmer D.

(Neuropsychiatr Genet), 1996.

56. Dallocchio C., Buffa C., Tinelli C.,

(Eds.). New York: Grune &

67
:139–46.

et al.
Effectiveness of risperidone
Stratton, pp. 267–86.

47. MacMillan J. C., Snell R. G., Tyler

in Huntington chorea patients.

38. Lovestone S., Hodgson S., Sham

A.,
et al.
Molecular analysis and

J Clin Psychopharmacol, 1999.

P.,
et al.
Familial psychiatric

clinical correlations of the

19
:101–3.

presentation of Huntington’s

Huntington’s disease mutation.

57. Parsa M. A., Szigethy E., Voci J.

disease. J Med Genet, 1996.

Lancet, 1993.
342
:954–8.

M.,
et al.
Risperidone in treatment
33
:128–31.

48. Weigell-Weber M., Schmid W.,

of choreoathetosis of Huntington’s

39. Tsuang D., DiGiacomo L., Lipe

Spiegel R. Psychiatric symptoms

disease. J Clin Psychopharmacol,

H.,
et al.
Familial aggregation of
and CAG expansion in

1997.
17
:134–5.

schizophrenia-like symptoms in

Huntington’s disease. Am J Med

58. Bogelman G., Hirschmann S.,

Huntington’s disease. Am J Med

Genet, 1996.
67
:53–7.

Modai I. Olanzapine and

Genet, 1999.
81
:323–7.

49. Wang S., Sun C. E., Walczak C. A.,

Huntington’s disease. J Clin

40. Tsuang D., Almqvist E., Lipe H.,

et al.
Evidence for a susceptibility
Psychopharmacol, 2001.
21
:245–6.

et al.
Familial aggregation of

locus for schizophrenia on

59. Reveley M. A., Dursum S. M.,

psychotic symptoms in

chromosome 6pter-p22.

Andrews H. A. Comparative trial

Huntington’s disease. Am J

Nat Genet, 1995.
10
:41–6.

use of sulpiride and risperidone in

Psychiatry, 2000.
157
:1955–9.

50. Riggins G. J., Lokey L. K.,

Huntington’s disease: a pilot

41. Correa B. B., Xavier M.,

Chastain J. L.,
et al.
Human genes
study. J Clin Psychopharmacol,

356

Guimaraes J. Association of

containing polymorphic

1996.
10
:162–5.

Chapter 28 – Huntington’s Disease and related disorders

60. van Vugt J., Siesling S., Vergeer

cystamine. Nat Med, 2002.

65. Andreasen N. C., Nopoulos P.,

M.,
et al.
Clozapine versus

8
:143–9.

O’Leary D. S.,
et al.
Defining the
placebo in Huntington’s disease:

phenotype of schizophrenia:

62. Schmahmann J. D., Pandya D. N.

a double blind randomised

cognitive dysmetria and its neural

The cerebrocerebellar system. Int

comparative study. J Neurol

mechanisms. Biol Psychiatry,

Rev Neurobiol, 1997.
41
:31–60.

Neurosurg Psychiatry, 1997.

1999.
46
:908–20.

63
:35–9.

63. Schmahmann J. D., Sherman J. C.

66. Kutty I. N., Prendes J. L. Psychosis

Cerebellar cognitive affective

61. Karpuj M. V., Becher M. W.,

and cerebellar degeneration.

syndrome. Int Rev Neurobiol,

Springer J. E.,
et al.
Prolonged

J Nerv Ment Dis, 1981.
169
:390–1.